Insecticides (India) Ltd. Q3 FY26 Investor Presentation Released
Insecticides (India) Limited reported Q3 FY26 revenue of ₹384.92 crore, up 8% YoY. PAT decreased 40% to ₹10.49 crore. For 9MFY26, revenue rose 4% to ₹1,713.75 crore, with PAT at ₹127.70 crore. The company released its investor presentation detailing financial performance and strategic initiatives.
The announcement provides detailed financial results for the quarter and nine months, along with an investor presentation. This information is crucial for investors to assess the company's performance and future outlook, thus having a medium impact.
The company reported mixed financial results with revenue growth but a significant decrease in profit for the quarter. The overall sentiment is neutral as positive revenue growth is offset by a decline in profitability.
Insecticides (India) Limited has released its investor presentation for the third quarter and nine months ended December 31, 2025. The presentation details the company's financial performance, operational highlights, and strategic roadmap.
The company reported a revenue of ₹384.92 crore for Q3 FY26, an 8% increase year-on-year from ₹357.70 crore in Q3 FY25. Gross profit for the quarter stood at ₹124.85 crore, a decrease of 3% from ₹129.19 crore in the previous year, leading to a Gross Profit Margin of 32.4% compared to 36.1% in Q3 FY25. EBITDA for the quarter was ₹27.39 crore, down 11% from ₹30.89 crore in Q3 FY25, with an EBITDA Margin of 7.1% versus 8.6% in the prior year. Profit After Tax (PAT) for Q3 FY26 was ₹10.49 crore, a 40% decrease from ₹17.36 crore in Q3 FY25, resulting in a PAT Margin of 2.7% compared to 4.9% in the previous year. Earnings Per Share (EPS) for the quarter was ₹3.60, down from ₹5.96 in Q3 FY25.
For the nine months ended December 31, 2025, revenue from operations increased by 4% to ₹1,713.75 crore from ₹1,641.03 crore in the corresponding period of FY25. Gross profit saw a 7% increase to ₹546.22 crore, with a Gross Profit Margin of 31.9% compared to 31.0% in 9MFY25. EBITDA for 9MFY26 was ₹201.45 crore, a 5% increase from ₹192.74 crore in 9MFY25, maintaining an EBITDA Margin of 11.8%. PAT for the nine months was ₹127.70 crore, a marginal decrease of 0.3% from ₹128.13 crore in 9MFY25, with a PAT Margin of 7.5% compared to 7.8% in the prior year. EPS for 9MFY26 stood at ₹43.89, slightly up from ₹43.52 in 9MFY25.
The presentation also highlighted the company's strategy, including premiumization of its product portfolio, aggressive product launches, integrated manufacturing capabilities, and an enhanced market presence. The company aims to strengthen its position through innovation and global partnerships. The investor presentation is available on the company's website.
What to do with a filing like this
Insecticides (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Insecticides (India) Limited. Read the original for the full detail.